- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:36 | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus | 1 | GlobeNewswire (USA) | ||
| 22.11. | Lipella rises after completing dosing of patient group in drug trial | 2 | Reuters | ||
| LIPELLA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 21.11. | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group | 54 | GlobeNewswire (Europe) | PITTSBURGH, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on innovative therapies for serious... ► Artikel lesen | |
| 12.11. | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform | 3 | GlobeNewswire (USA) | ||
| 05.11. | Lipella Pharmaceuticals-Aktie erreicht 52-Wochen-Tief bei 0,32 US-Dollar | - | Investing.com Deutsch | ||
| 05.11. | Lipella Pharmaceuticals stock hits 52-week low at $0.32 | 5 | Investing.com | ||
| 01.11. | LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.11. | Lipella Pharmaceuticals announces 1-for-8 reverse stock split | 1 | Investing.com | ||
| 01.11. | Lipella Pharmaceuticals kündigt Aktienzusammenlegung im Verhältnis 1:8 an | 1 | Investing.com Deutsch | ||
| 01.11. | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split | 91 | GlobeNewswire (Europe) | PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the "Company," "our" or "us"), a clinical-stage biotechnology company focused on developing innovative therapies... ► Artikel lesen | |
| 18.10. | Lipella Pharmaceuticals droht Delisting von der Nasdaq aufgrund von Eigenkapitalmangel | 1 | Investing.com Deutsch | ||
| 18.10. | Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall | 1 | Investing.com | ||
| 18.10. | LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.10. | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform | 116 | GlobeNewswire (Europe) | Patent application covers key technology innovations for delivering therapeutic agentsProprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer survivorship... ► Artikel lesen | |
| 09.10. | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit | 1 | GlobeNewswire (USA) | ||
| 24.09. | Lipella reports positive phase 2a trial results for OLP treatment | 1 | Investing.com | ||
| 11.09. | LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.08. | LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.08. | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research | 144 | GlobeNewswire (Europe) | Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouthNo FDA-approved therapy currently exists for OLPPatient registry and OLP study... ► Artikel lesen | |
| 21.08. | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,430 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,379 | +1,61 % | Defence Therapeutics will proprietäre Accum-Technologie an Entwickler von Antikörper-Wirkstoff-Konjugaten (ADC) lizenzieren | Vancouver, BC, Kanada, 29. November 2024 / IRW-Press / Defence Therapeutics Inc. ("Defence" oder das "Unternehmen") (CSE: DTC, OTCQB: DTCFF, FWB: DTC), ein kanadisches biopharmazeutisches
Unternehmen... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,800 | -4,35 % | Ginkgo Bioworks Reports Third Quarter 2024 Financial Results | Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions
Ginkgo... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,270 | -4,03 % | Recursion Pharmaceuticals, Inc.: Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma | First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesizedREC-1245... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,480 | -6,43 % | Beam Therapeutics Inc. Q3 Loss Misses Estimates | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) reported Loss for third quarter that missed the Street estimates.The company's earnings came in at -$96.668 million, or -$1.17 per share.... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,860 | -3,91 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort | Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 18,100 | -2,74 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,987 | -3,74 % | Assertio Holdings, Inc.: Assertio Reports Third Quarter 2024 Financial Results | Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,680 | -6,57 % | Why SIGA Technologies (SIGA) Is One of the Most Profitable Pharmaceutical Stocks Right Now? | ||
| ADMA BIOLOGICS | 19,760 | +0,36 % | Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge | ||
| VIR BIOTECHNOLOGY | 9,190 | +12,83 % | Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients | ||
| VERVE THERAPEUTICS | 7,330 | +2,73 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 18,300 | -2,14 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| ARVINAS | 25,040 | -2,64 % | Arvinas Inc.: Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update | - On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 - - Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented... ► Artikel lesen | |
| BIO-PATH | 0,755 | +1,62 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Third Quarter 2024 Financial Results | Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology... ► Artikel lesen |
Das Unternehmen LIPELLA PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,870 Euro und damit -7,72 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIPELLA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
